Cloudbreak Therapeutics is a clinical-stage biotechnology company focusing on ocular drug development. Our mission is to help people see life better through medicine.
Founded September, 2015 in Irvine, California, USA, Cloudbreak Therapeutics quickly advanced our first drug candidate through lead selection, pre-clinical IND-enabling studies and successful IND submission. Cloudbreak Therapeutics already completed Phase II clinical trial for its first drug candidate which is a disease modifying, first-in-class, and first drug therapy to treat pterygium. Fully embracing the pharmaceutical development ecosystem, Cloudbreak Therapeutics utilizes contract research organizations (CRO) for non-clinical, CMC and clinical development to efficiently maximize capital for drug development.